Submit your email to push it up the queue
Zentiva, a leading pharmaceutical company headquartered in the Czech Republic (CZ), has established itself as a key player in the generic and specialty medicines sector since its founding in 2003. With a strong presence across Europe, Zentiva focuses on delivering high-quality, affordable healthcare solutions that cater to diverse patient needs. The company’s core offerings include a wide range of generic medications, over-the-counter products, and specialty pharmaceuticals, all designed to enhance patient access to essential treatments. Zentiva is recognised for its commitment to quality and innovation, ensuring that its products meet rigorous industry standards. Notable achievements include expanding its operational footprint in major European markets, positioning Zentiva as a trusted partner in healthcare. With a dedication to sustainability and patient-centric solutions, Zentiva continues to make significant strides in the pharmaceutical industry.
How does Zentiva's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zentiva's score of 86 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Zentiva reported total carbon emissions of approximately 411,860,000 kg CO2e. This figure includes 13,722,000 kg CO2e from Scope 1 emissions, 14,088,000 kg CO2e from Scope 2 emissions (market-based), and a significant 384,050,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (about 308,083,000 kg CO2e) and upstream transportation and distribution (approximately 19,344,000 kg CO2e). Comparatively, in 2023, Zentiva's total emissions were about 81,444,000 kg CO2e, with Scope 1 emissions at 15,038,000 kg CO2e, Scope 2 emissions (market-based) at 13,607,000 kg CO2e, and Scope 3 emissions totalling approximately 52,799,000 kg CO2e. This indicates a substantial increase in emissions from 2023 to 2024. Zentiva's emissions data is cascaded from its parent company, Sanofi, reflecting a corporate family relationship. However, there are currently no specific reduction targets or climate pledges disclosed by Zentiva. The company is committed to sustainability initiatives, but detailed reduction strategies or targets have not been provided in the available data. Overall, Zentiva's emissions profile highlights the significant impact of Scope 3 emissions, particularly from purchased goods and services, underscoring the importance of addressing supply chain emissions in their climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|
Scope 1 | 20,652,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 13,171,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 44,607,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zentiva is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.